Collaborations & Alliances, Trials & Filings

Amneal Launches Nexium Alternative

Releases 505(b)(2) product in parternship with Hanmi

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Amneal Pharmaceuticals has launched its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease (GERD). Amneal is marketing the 505(b)(2) product in the U.S. under an exclusive license and distribution agreement wi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters